GlassScriptPhysician profile
Howard S Ying
NPI 1841236791
$12,115.37
in general payments reported to CMS, 2019-2025
24 companies · $3,225 in 2025
The $3,225 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $651 · 2021: $526 · 2022: $939 · 2023: $2,275 · 2024: $3,550 · 2025: $3,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,154 · Honoraria: $1,390 · Long Term Medical Supply Or Device Loan: $337 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,153.79 |
| Honoraria | $1,390.00 |
| Long Term Medical Supply Or Device Loan | $336.52 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $2,528.01 | 2019-2024 | Yutiq, Iluvien |
| Mallinckrodt Hospital Products INC. | $1,833.65 | 2020-2025 | Acthar |
| Abbvie INC. | $1,714.21 | 2019-2025 | Durysta, Ozurdex |
| Alcon Vision LLC | $984.42 | 2019-2025 | Constellation, Unity |
| Ani Pharmaceuticals, INC. | $864.54 | 2024-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Genentech USA, INC. | $859.28 | 2022-2025 | Vabysmo |
| Astellas Pharma US INC | $833.31 | 2023-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $369.68 | 2019-2025 | Eylea Hd |
| Sun Pharmaceutical Industries INC. | $267.74 | 2019-2025 | |
| Sandoz INC. | $262.48 | 2024-2025 | Cimerli |
| Dompe US, INC. | $256.70 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $225.37 | 2024-2025 | Xdemvy |
| Allergan, INC. | $199.97 | 2019-2021 | |
| Genentech, INC. | $147.78 | 2025 | Vabysmo |
| Eyepoint US, INC. | $145.38 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $144.35 | 2021 | |
| Horizon Therapeutics Plc | $121.97 | 2022-2023 | Tepezza |
| Coherus Oncology, INC. | $104.57 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $62.16 | 2019 | |
| Mallinckrodt Enterprises LLC | $60.25 | 2019 | |
| Apellis Pharmaceuticals, INC. | $56.45 | 2022-2023 | Syfovre |
| Oyster Point Pharma, INC. | $34.92 | 2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $19.67 | 2025 | Miebo |
| Amgen INC. | $18.51 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Ying listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.